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Chemotherapy in non–small cell lung
cancer: An update of an individual
patient data-based meta-analysis
To the Editor:
In the September 2004 issue of the Journal,
Sedrakyan and associates1 reported a sys-
tematic review and meta-analysis of post-
operative chemotherapy versus surgery
alone in non–small cell lung cancer. This
meta-analysis is based on abstracted data
from 15 randomized controlled trials
(RCTs). This included 7200 patients and
builds on results of our individual patient
data-based (IPD) meta-analysis,2 published
in 1995.
The Non–Small Cell Lung Cancer
Collaborative Group, which was respon-
sible for the IPD meta-analysis published
in 1995, welcomes the meta-analysis pro-
vided by Sedrakyan and associates,1
which added summary data from 7 trials
and approximately 5000 patients to infor-
mation from the 1995 meta-analysis.
However, the interpretation of the results
is limited by the absence of trial descrip-
tion and quality evaluation. Furthermore,
the results of any systematic review per-
formed with data extracted from publica-
tions of trials should be viewed with a
degree of caution.3
IPD meta-analyses, which involve the
central collection, validation, and analy-
sis of the original trial data, are the gold
standard of systematic review and have
many advantages over literature-based
approaches. They allow the reviewer to
check the data, ensure the randomization
process was adequate, investigate heter-
ogeneity, and report longer follow-up,
and can limit many biases.4 They also
permit subgroup analysis of patient level
characteristics such as age or tumor
stage. Of course, it is also well docu-
mented that this type of review takes
longer to carry out.
The 1995 meta-analysis included more
than 9000 patients from 52 RCTs and as-
sessed the effect of chemotherapy in 4 dif-
ferent settings.
An updated and extended IPD meta-
analysis is currently under way, and data
collection is ongoing. New agents and tim-
ings have been investigated in all settings.
The update consists of adding trials pub-
lished since the 1995 analyses and addi-
tional follow-up data from trials already
included, and investigating additional out-
comes in certain settings. Seven different
therapeutic questions will be addressed,
and the total number of patients random-
ized has increased to approximately 23,000
patients. The corresponding protocols are
available at the following websites: http://
www.ctu.mrc.ac.uk/download.asp or http://
www.igr.fr / php /index.php?ids_path2.51.
70.127.567.
In a setting equivalent to that described
by Sedrakyan and associates,1 we identi-
fied 22 new RCTs with more than 8000
new patients, bringing the total number of
trials to 38. If we can include these pa-
tients, it would bring the total number of
patients in this comparison alone to more
than 10,500 patients or 23% more patients
than are included in the review by Se-
drakyan and associates.1
Although the meta-analyses by Se-
drakyan and associates1 and a recent sim-
ilar review by Hotta and associates5 are a
valuable resource in the absence of other
evidence, the results should be consid-
ered with caution until they can be com-
pared with the updated IPD meta-analy-
sis. We anticipate that the results of our
IPD meta-analyses will be available in
2006.
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Reply to the Editor:
We support and applaud the efforts of Ms
Burdett and her team in conducting an indi-
vidual patient data-based (IPD) meta-analysis
of postoperative chemotherapy trials. Al-
though there are controversies regarding the
conduct of IPD meta-analyses, such as the
inclusion of data from unpublished studies
and potential investigator bias in terms of
data submitted,1,2 such studies may be par-
ticularly useful in conducting subgroup anal-
yses to identify those patients most likely to
benefit from therapy and the optimal treat-
ment regimen to be used.
The non-IPD nature of our meta-analysis
does not, however, take away from the valid-
ity of the findings that clearly demonstrate a
survival advantage for patients treated with
adjuvant chemotherapy over those treated
with surgery alone.3 This is also underpinned
by a recent presentation on adjuvant UFT
(uracil and tegafur), the oral 5-fluorouracil
derivative, at the 2004 annual meeting of the
American Society of Clinical Oncology. In
this work, individual patient data from 2003
patients recruited to 6 randomized controlled
trials were systematically reviewed. The
overall survival benefit for treated patients is
5.3% (hazard ratio  0.77; P  .011) at 5
years and 7.7% (hazard ratio  0.74; P 
.001) at 7 years. This is similar to our re-
ported survival benefit for UFT. In addition,
continued divergence of the survival curves
over time is similar to those commonly seen
in breast cancer adjuvant trials.4
The authors are correct that since our pub-
lication, further randomized controlled trials
have been presented. The 2 largest and prin-
cipal new studies presented at the 2004 meet-
ing of the American Society of Clinical On-
cology for platinum-based chemotherapy,
however, reported substantial benefits associ-
ated with adjuvant chemotherapy.5,6 Com-
bining the results of these trials with the pre-
vious randomized controlled trials evaluating
platinum-based regimens has demonstrated a
further overall benefit for platinum-based
postoperative chemotherapy (relative risk,
0.86; 95% confidence interval, 0.80-0.93).
Moreover, sensitivity analyses determined
that even if there were unreported or future
studies enrolling more than 2000 patients that
showed a statistically significant 20% higher
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